Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3902 - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment – single center experience in setting of no reimbursement in Poland (2011-2015)

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Agnieszka Badora-Rybicka

Citation

Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240

Authors

A. Badora-Rybicka1, A. Polakiewicz-Gilowska1, A. Leśniak1, W. Bal2, M. Kubeczko1, K. Świderska1, M. Mianowska-Malec1, B.D. Grandys1, E. Stobiecka3, E. Chmielik3, A. Kuś4, R. Tarnawski1, M. Jarzab1

Author affiliations

  • 1 Iii Department Of Radiotherapy And Chemotherapy, Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, 44-101 - Gliwice/PL
  • 2 Ambulatory Chemotherapy Department, Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, 44-101 - Gliwice/PL
  • 3 Tumor Pathology Department, Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, 44-101 - Gliwice/PL
  • 4 Ambulatory, Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, 44-101 - Gliwice/PL
More

Resources

Abstract 3902

Background

Targeted anti-HER2 therapy is a keystone in radical breast cancer therapy. In Poland preoperative use of trastuzumab was not reimbursed until 2016 and pertuzumab is still not covered. Moreover, adjuvant use of trastuzumab was not covered for patients with stage IIIB-C breast cancer. The aim of the study was to analyse of the subset of patients with HER2-positive breast cancer who were treated preoperatively in s center in Poland without use of anti-HER2 medications to analyse their prognosis compared to other breast cancer subtypes.

Methods

We reviewed the records of patients enrolled to the prospective study of prediction of chemotherapy response (MILESTONE-BreastPred). All patients were enrolled between 2011—2015, with intent of preoperative breast cancer chemotherapy, mainly by AC-P or TAC regimens. In the whole group PET/CT was used as an method of staging.

Results

Table:

197P

SubtypeHER2-positiveTNBCLUM B HER2-negativeP
numer of patients11987160
median age4742.746.6n.s.
% G366.486.147.40.001
% N + 74.860.967.5n.s.
% CSIII56.242.938.80.048
% de novo CSIV11.93.58.1n.s.
% inoperable after chemotherapy [%]17.710.310n.s.
% pCR32.6539.7420.140.005
% 5-year PFS47.270.668.30.001
median PFS [mo]56.7NR92.90.001

Conclusions

HER2-positive breast cancer in Polish population is at presentation more advanced than other subtypes, and despite relatively high pCR rate, has poor prognosis, when treated without sufficient anti-HER2 therapy. Prognosis in HER2-positive breast cancer in the analysed subgroup of Polish patients was poorer than in TNBC. The results underline the importance of treatment according to international guidelines and speak in favour of including anti-HER2 therapy preoperatively. The study was supported by the Polish National Center of Research and Development MILESTONE project – Molecular diagnostics and imaging in individualized therapy for breast, thyroid and prostate cancer, grant no. STRATEGMED 2/267398/4/NCBR/2015.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

the Polish National Center of Research and Development MILESTONE project – Molecular diagnostics and imaging in individualized therapy for breast, thyroid and prostate cancer, grant no. STRATEGMED 2/267398/4/NCBR/2015.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings